Clinical Trial

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Phase I/IIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of INR102 injection in patients with prostate cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-05.
Status change: Not Yet Recruiting → Recruiting 2026-01-04
Trial Details
NCT Number NCT06970119
Lead Sponsor Yunhe Pharmaceutical (Tianjin) Co., Ltd
Conditions Prostate Cancer
Enrollment 55 participants
Start Date 2025-05-14
Primary Completion 2029-06-20 (estimated)
Study Completion 2029-10-22 (estimated)
Updated on ClinicalTrials.gov 2026-01-07